“Human-breast cancer—Correlation of relapse and survival with amplification of the HER-2 neu oncogene” was published in Science in 1987 (IF 56.9) and has been cited 9,708 times, “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic BC that overexpresses HER2” was published in the New England Journal of Medicine (IF 158.9) in 2001 and has been cited 8,923 times, and “Studies of the HER-2/Neu proto-oncogene in human-breast and ovarian-cancer” was published in Science (IF-56.9) in 1989 and has been cited 6,186 times. This evidence concerns the gene ERBB2 and ovarian carcinoma.